To screen or not to screen: complexity of SDHA mutation management

Endocrine Oncology · Published 2026-01-01 · DOI 10.1530/eo-25-0048

Authors being retrieved — see the publisher record. https://doi.org/10.1530/eo-25-0048

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

HbA1c screening in patients with early breast cancer receiving endocrine therapy · Endocrine Oncology · 2025 · Same journal
Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas · Endocrine Oncology · 2025 · Same journal
Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE · Endocrine Oncology · 2025 · Same journal
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence · Endocrine Oncology · 2025 · Same journal
Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes · Endocrine Oncology · 2025 · Same journal
Adrenal crisis due to pembrolizumab-induced hypophysitis in a patient with triple-negative breast cancer · Endocrine Oncology · 2025 · Same journal
Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer · Endocrine Oncology · 2025 · Same journal
Patient-reported symptom and urgent healthcare use in neuroendocrine tumors · Endocrine Oncology · 2026 · Same journal
Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute · Endocrine Oncology · 2025 · Same journal
CHEK2 Germline Gene Variant in a Patient with a Somatotrophinoma and Primary Hyperparathyroidism – A Novel MEN1-like Syndrome? · Endocrine Oncology · 2026 · Same journal